Hyperlipidemia does not influence clinical outcome in arthroscopic treatment of femoroacetabular impingement syndrome.

J Orthop Surg Res

Department of Sports Medicine, Beijing Key Laboratory of Sports Injuries, Institute of Sports Medicine of Peking University, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing, 100191, People's Republic of China.

Published: August 2022

Background: Cholesterol can trigger degenerative processes in the chondrocytes. The internal layer of the hip labral consists of cartilage-specific type II collagen-positive fibrocartilage. The purpose of this study was to compare outcomes after arthroscopy labral repair in FAIS patients with preoperative hyperlipidemia to a control group with no hyperlipidemia.

Methods: Data were prospectively collected and retrospectively reviewed for FAIS patients who had arthroscopy 2019. Patients with hyperlipidemia were 1:1 propensity-score matched to patients without hyperlipidemia. Patient-reported outcomes (HOS-ADL, iHOT-12, mHHS), VAS scores, radiographic measures, performed procedures, complications, and revision surgery were compared and analyzed for both groups.

Results: A total of 41 patients with hyperlipidemia and 41 patients without hyperlipidemia were found using propensity-score matching. When compared to preoperative levels, both groups demonstrated significant improvements in PROs and VAS scores at the final follow-up. Besides, there were no significant differences in preoperative scores and final outcome scores between the groups. Besides, there were no other differences in revision rate and the rate of meeting the PASS and MCID between the study and the control groups.

Conclusion: It was demonstrated in this study that FAIS patients with hyperlipidemia can expect to experience similar good short-term patient-reported outcomes as compared with patients without hyperlipidemia.

Level Of Evidence: Case-series study; Level of Evidence: Level III.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429662PMC
http://dx.doi.org/10.1186/s13018-022-03290-3DOI Listing

Publication Analysis

Top Keywords

patients hyperlipidemia
20
fais patients
12
patients
8
hyperlipidemia propensity-score
8
patient-reported outcomes
8
vas scores
8
scores final
8
hyperlipidemia
7
hyperlipidemia influence
4
influence clinical
4

Similar Publications

Background: With the aging of the population, the deterioration of visual and auditory functions amongst the elderly has attracted much attention. Age-related hearing loss (ARHL) and age-related macular degeneration (AMD) are common eye and ear diseases that seriously affect the quality of life of elderly population.

Methods: This study utilised a whole cohort sampling method, with a total of 713 participants aged 50 years and older in the community from June 2022 to October 2023, resulting in the inclusion of 620 participants.

View Article and Find Full Text PDF

Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field.

Curr Atheroscler Rep

January 2025

Unitat de Medicina Vascular I Metabolismo, Hospital Universitario Sant Joan, Universitat Rovira I Virgili, IISPV, CIBERDEM, Reus, Spain.

Purpose Of The Review: A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.

Recent Findings: Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes.

View Article and Find Full Text PDF

Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities.

Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Laboratory of Neuro Imaging (LONI), University of Southern California, Los Angeles, CA, USA.

Background: Screen failure due to amyloid negativity is yet a problem in clinical trials for anti-amyloid drugs. In this context, clinical characteristics of patients presenting with cognitive decline may decrease the screen failure ratio by increasing the odds of selecting individuals with brain amyloid pathology. Herein, we aimed at estimating amyloid and tau positivity in individuals using clinical variables in a machine learning model of prediction.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

Eisai Inc., Woodcliff Lake, NJ, USA.

Background: This study aims to describe usage patterns and risk factors associated with anticoagulant therapy in patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD).

Methods: The United States Medicare claims database (2008- 18) was used to identify patients aged ≥65 years with MCI or AD and to evaluate their anticoagulant use from 2016- 17. A random sample of new anticoagulant users (n = 21,069) was selected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!